儿童和青少年伤寒结合疫苗真实世界疫苗有效性的系统综述与Meta分析
该系统综述与Meta分析纳入4项上市后观察性研究、共24,180人,评估单剂Typbar TCV®对比未接种儿童的疫苗有效性。结果显示针对培养确诊伤寒的VE为87%(95%CI 57-94%),针对广泛耐药株的VE为97%(95%CI 95-98%)。作者认为结果支持在伤寒流行国家将TCV纳入国家免疫规划。
要点
- 单剂Typbar TCV®对培养确诊伤寒的VE为87%(95%CI 57-94%)。
- 对广泛耐药伤寒的VE为97%(95%CI 95-98%)。
- 敏感性分析提示接种后4-5年保护力显著下降。
核心结论
- 伤寒结合疫苗在流行地区对培养确诊、疑似、可能及广泛耐药伤寒均显示显著的真实世界有效性。
- 该系统综述与Meta分析支持在伤寒流行国家将TCV纳入国家免疫规划。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE(PubMed)、EMBASE、Web of Science和Cochrane Library,纳入截至2025年8月14日发表的上市后观察性及非随机研究。
- Meta分析纳入4项研究,共24,180人,来自巴基斯坦、印度和津巴布韦三个国家,比较单剂Typbar TCV®接种者与未接种儿童。
- 方案注册于PROSPERO(CRD42023456130)。
主要发现
- TCV对培养确诊伤寒的VE为87%(95%CI 57-94%)。
- TCV对疑似、可能和培养确诊伤寒合并结局的VE为55%(95%CI 0.52-57%)。
- TCV对广泛耐药(XDR)伤寒的VE为97%(95%CI 95-98%)。
- 敏感性分析(8项研究、5个国家)提示5岁以上儿童VE较高,且接种后4-5年保护力显著下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Typhoid fever, caused by Salmonellaenterica serovar Typhi (S. Typhi), can be transmitted via faecal-oral route. Although significant reduction in incidence from 11 million in 2017 to 7 million in 2021, typhoid fever remains a global health problem. The World Health Organization (WHO) recommended implementation of typhoid conjugate vaccine (TCV) in endemic countries. However, only ten countries have introduced TCV into their national immunisation programs to date. This study aims to estimate the real-world effectiveness of TCV to inform evidence-based decision making and support implementation in typhoid-endemic countries. METHODS: In this systematic review and meta-analysis (SRMA), we searched MEDLINE (PubMed), EMBASE, Web of Science, and Cochrane Library. We included post-licensure observational and non-randomised studies evaluating vaccine effectiveness (VE) of TCV among children and adolescents published up to August 14th, 2025. Four TCV vaccines - Typbar TCV®, TYPHIBEV®, SKYTyphoid™, and ZyVac® TCV- had been WHO-prequalified at the time of review. The protocol is registered with PROSPERO (CRD42023456130). RESULTS: We identified 1337 records and included four studies in the meta-analysis, comprising 24,180 individuals from three countries (Pakistan, India, and Zimbabwe) comparing single-dose Typbar TCV® recipients with unvaccinated children. TCV prevented culture-confirmed typhoid with VE of 87 % (95 % CI, 57-94 %). TCV also prevented combined suspected, probable, and culture-confirmed typhoid with VE of 55 % (95 % CI, 0.52-57 %) and extensively drug-resistant (XDR) S. Typhi with VE of 97 % (95 % CI, 95-98 %). Sensitivity analysis (eight studies, five countries; see Supplementary File) indicated a higher VE among older children (above 5 years) and a significant decline in protection 4-5 years after vaccination. CONCLUSION: Typhoid conjugate vaccines (TCV) demonstrate significant real-world effectiveness in preventing culture-confirmed, probable, suspected, and extensively drug-resistant (XDR) typhoid cases in endemic regions. This systematic review and meta-analysis support the implementation of TCV into national immunisation programs in typhoid-endemic countries. SIGNIFICANCE: No previously published systematic review and meta-analysis evaluate the effectiveness of TCV. Evidence on real-world effectiveness is needed to support typhoid endemic countries considering the introduction of TCV into their national immunisation program.
引用
- Haposan JH, Icanervilia AV, Watts E, et al. Real-world vaccine effectiveness of typhoid conjugate vaccine in children and adolescents: a systematic review and meta-analysis. Vaccine. 2025. PMID: 41125003. doi:10.1016/j.vaccine.2025.127872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。